How many insider declarations has Kim Christopher filed?

Kim Christopher has filed 2 public insider declarations with SEC (Form 4).

What is Kim Christopher's role?

Kim Christopher's reported role is not specified by the regulator across the filings.

Which companies does Kim Christopher report trades for?

Kim Christopher reports trades for Apimeds Pharmaceuticals US, Inc..

What is Kim Christopher's declared buy vs sell volume?

Across the available history, declared buys total 32k€ and disposals 0.

← Executives ★ Sign in to follow

KC

Kim Christopher

CHAIRMAN

·SEC (Form 4)

Apimeds Pharmaceuticals US, Inc.

0

申报总数

0

公司

€32,168

▲ 买入（1 笔）

—

▼ 卖出（0 笔）

内部人交易记录

其他

已披露买入

1

已披露卖出

0

T+90 胜率

0%

T+90 平均收益

-6.8%

基于 1 个已确定 T+90 收益的买入信号。收益基准：公布次日的收盘价。

信号历史

无可用的信号评分。

Browse the complete record of transactions filed by Kim Christopher. Officer active across 1 company, notably Apimeds Pharmaceuticals US, Inc.. In total, 2 reports have been recorded. Breakdown: 1 buy · 0 sell. Total volume traded: €32k. History available since 13 May 2025. The latest transaction was filed on 16 May 2025 (Attribution). Regulator: SEC (Form 4). All data is openly available.

Companies and markets linked to Kim Christopher

Open company profiles for insider transactions, fundamentals and analyst consensus when available.

Apimeds Pharmaceuticals US, Inc. (US)

申报2 总计

◆

Kim Christopher

Chairman and CMO高管2025年5月16日Apimeds Pharmaceuticals US, Inc.

0SEC ↗

250,000 股0Common Stock, par value $0.01 per shareSEC:0001474506-25-000100:0

▲

Kim Christopher

Chairman and CMO高管2025年5月13日Apimeds Pharmaceuticals US, Inc.

US$35,98138SEC ↗

19,770 股@ US$1.82100.0% 占其流量Common Stock, par value $0.01 per shareSEC:0001474506-25-000096:0

标准退出：2025年8月11日 (T+90)

2 条申报中的 2 条

InsidersTradesSigma

← Executives ★ Sign in to follow

KC

Kim Christopher

CHAIRMAN

·SEC (Form 4)

Apimeds Pharmaceuticals US, Inc.

0

申报总数

0

公司

€32,168

▲ 买入（1 笔）

—

▼ 卖出（0 笔）

内部人交易记录

其他

已披露买入

1

已披露卖出

0

T+90 胜率

0%

T+90 平均收益

-6.8%

基于 1 个已确定 T+90 收益的买入信号。收益基准：公布次日的收盘价。

信号历史

无可用的信号评分。

Browse the complete record of transactions filed by Kim Christopher. Officer active across 1 company, notably Apimeds Pharmaceuticals US, Inc.. In total, 2 reports have been recorded. Breakdown: 1 buy · 0 sell. Total volume traded: €32k. History available since 13 May 2025. The latest transaction was filed on 16 May 2025 (Attribution). Regulator: SEC (Form 4). All data is openly available.